Business Context and Reporting Period
Company: GSK plc (LSE/NYSE: GSK)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: June 2026 (Issued June 12, 2026)
Subject: Regulatory milestone for momelotinib regarding VEXAS syndrome.
Key Financial Metrics
This filing is a current report regarding a regulatory development and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Developments
- Orphan Drug Designations (ODD): Momelotinib received ODD from both the US FDA and the European Medicines Agency (EMA) for the treatment of VEXAS syndrome.
- Target Condition: VEXAS syndrome is a rare, life-threatening haemato-inflammatory condition with no currently approved treatments and a 30-40% five-year mortality rate.
- Clinical Trial Progress: The ATLAS phase II/III trial evaluating momelotinib in VEXAS is underway. The study design is scheduled for presentation at the 2026 European Hematology Association (EHA) Congress.
- Existing Approvals: Momelotinib (Ojjaara/Omjjara) remains approved for myelofibrosis in the US, EU, UK, and Japan.
Outlook, Risks, and Management Commentary
- Strategic Rationale: The ODDs support development efforts and regulatory evaluations for this rare disorder. Evidence supporting the designation includes retrospective case studies and a case report indicating potential clinical benefit.
- Mechanism of Action: Momelotinib inhibits JAK1, JAK2, and ACVR1 pathways, potentially addressing inflammation and anaemia associated with VEXAS.
- Risk Factors: The filing includes a cautionary statement that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's 2025 Annual Report on Form 20-F and Q1 2026 Results.
Investor Verification Checklist
- Verify the specific endpoints and enrollment status of the ATLAS phase II/III trial (NCT07569081).
- Review the "Risk Factors" in the 2025 Form 20-F and Q1 2026 results for details on regulatory approval uncertainties.
- Monitor the presentation of the study design at the 2026 EHA Congress (June 11-14, 2026).
- Assess the competitive landscape for VEXAS syndrome treatments, given the current lack of approved therapies.